7.4highGO

Clinical Note Quality Scorer

Automated audit tool that scores AI-generated clinical notes for accuracy, completeness, and coding optimization

FinanceHealth system quality teams, compliance officers, and revenue cycle managers
The Gap

Even when AI scribes save time, note quality and proper coding (HCCs) vary wildly - there's no standardized way to measure if AI notes are actually good

Solution

Scans AI-generated notes against clinical guidelines, coding requirements, and payer rules to score quality, flag errors, and identify revenue leakage from miscoded encounters

Revenue Model

SaaS per-encounter pricing ($0.50-2 per note) or monthly subscription

Feasibility Scores
Pain Intensity8/10

The JAMA study you referenced is a watershed moment — it proved AI scribe quality is inconsistent. Compliance officers are terrified of audit risk from AI-generated notes. Revenue cycle teams know miscoded HCCs = millions in leaked revenue. Quality teams have no standardized way to measure AI note quality across vendors. The pain is real, urgent, and tied to both regulatory risk and direct revenue impact. Docking 1 point because many health systems are still in early AI scribe adoption and haven't yet felt this pain acutely.

Market Size7/10

TAM estimate: ~1M US physicians generating ~3B ambulatory encounters/year. If 30% are AI-scribed within 3 years = ~900M encounters. At $0.50-2/encounter, that's a $450M-1.8B TAM. Realistic SAM in years 1-3 is $50-150M targeting large health systems and quality-conscious groups. Not a massive TAM compared to the scribe market itself, but solid for a SaaS startup. The per-encounter model scales naturally with AI scribe adoption.

Willingness to Pay7/10

Health systems already pay $3-8/chart for retrospective coding review (Apixio, Reveleer). $0.50-2/note for prospective quality scoring is cheap by comparison, especially if you can demonstrate even 1-2% revenue uplift from coding optimization. Compliance risk alone justifies the spend — a single OIG audit finding on AI-generated notes could cost millions. The buyer (quality/compliance/rev cycle) has budget authority. Docking points because health system procurement is slow and new budget line items face resistance.

Technical Feasibility6/10

A solo dev can build a functional MVP in 4-8 weeks that ingests notes and runs rule-based quality checks against coding guidelines. BUT: the hard part is clinical accuracy — you need validated clinical logic, up-to-date HCC coding rules (ICD-10-CM/HCC mapping changes annually), and payer-specific rule sets. LLMs can help but hallucination risk in clinical contexts is a liability. You'll need clinical advisor input and likely HIPAA-compliant infrastructure from day one. Not impossible but more complex than typical SaaS.

Competition Gap8/10

This is the strongest signal. NO existing product specifically scores AI-generated clinical notes as an independent third party. Existing CDI tools audit human notes. AI scribe vendors grade their own work. There is a genuine white-space opportunity for an independent AI note quality auditor. The 'fox guarding the henhouse' problem with scribe vendors self-reporting quality is a powerful positioning angle.

Recurring Potential9/10

Textbook recurring revenue. Every encounter generates a note that needs scoring. Volume grows as AI scribe adoption increases. Health systems won't turn off quality monitoring once implemented — it becomes part of compliance infrastructure. Per-encounter pricing naturally scales with usage. Switching costs increase as historical quality trend data accumulates.

Strengths
  • +Clear white-space: no independent third-party AI note quality scorer exists today
  • +Picks-and-shovels play — grows automatically as AI scribe adoption accelerates
  • +Multiple buyer personas with budget: quality teams, compliance, revenue cycle
  • +Direct ROI story: coding optimization pays for the tool many times over
  • +Regulatory tailwinds: CMS/OIG scrutiny of AI-generated documentation is increasing
  • +Per-encounter pricing model is familiar to healthcare buyers and scales naturally
Risks
  • !AI scribe vendors (Nuance, Abridge, Fathom) could build quality scoring into their own platforms, reducing need for third-party tool
  • !Health system procurement cycles are 6-18 months — long time to first enterprise deal
  • !Clinical validation is table stakes: one false quality flag in a clinical context destroys credibility
  • !HIPAA compliance, SOC 2, and potentially HITRUST certification required before enterprise sales — adds time and cost
  • !EHR integration complexity (Epic, Cerner, etc.) could be a bottleneck for data ingestion
Competition
Nuance/DAX Copilot (Microsoft)

AI-powered ambient clinical documentation that generates notes from patient-physician conversations, with built-in quality metrics and coding suggestions

Pricing: ~$200-400/provider/month bundled with DAX; quality analytics not sold separately
Gap: Quality scoring is internal to their own notes — no independent audit layer, no cross-vendor benchmarking, no focus on scoring COMPETING AI scribe outputs. They grade their own homework.
Iodine Software

AI-driven clinical documentation integrity and CDI

Pricing: Enterprise SaaS, typically $1-3M+/year for large health systems
Gap: Built for human-authored notes, not specifically designed to audit AI-generated documentation. No AI scribe quality benchmarking. Very expensive — inaccessible to mid-market. Focused on coding uplift, not holistic note quality.
Fathom / Abridge / Ambience (AI Scribe vendors with internal QA)

Leading AI ambient scribe companies that include some internal quality checks and note accuracy metrics within their platforms

Pricing: $99-350/provider/month for the scribe product; QA is bundled, not standalone
Gap: Conflict of interest — they only score their OWN notes. No independent third-party validation. No cross-platform quality benchmarking. Health systems using multiple scribes have no unified quality view. Compliance officers don't trust vendor self-reporting.
Apixio / Reveleer

AI-powered risk adjustment and retrospective chart review platforms that analyze clinical documentation for HCC coding accuracy and revenue optimization

Pricing: Per-chart or per-member-per-month pricing, typically $3-8 per chart review
Gap: Retrospective only — reviews charts after the fact, not at point of care. Not designed for real-time AI note quality scoring. No prospective quality feedback loop. Doesn't address the specific problem of AI scribe output variability.
MVP Suggestion

Start with a web app that accepts uploaded/pasted AI-generated clinical notes (no EHR integration yet). Score notes against three dimensions: (1) HCC coding completeness — flag missed diagnoses that should have been coded, (2) documentation compliance — check for required elements per CMS E/M guidelines, (3) clinical consistency — flag contradictions within the note. Output a quality scorecard with specific improvement suggestions. Target 3-5 beta health systems willing to manually export notes for review. Focus on one specialty (primary care or internal medicine) where HCC coding matters most.

Monetization Path

Free pilot (50 notes) to demonstrate ROI -> Per-encounter pricing ($0.50-1/note) for individual practices -> Monthly subscription ($2K-10K/month) for health system departments -> Enterprise platform license ($100K-500K/year) with EHR integration, dashboards, and benchmarking -> Expand to payer-side (health plans auditing their delegated provider AI notes) for $1M+ contracts

Time to Revenue

8-14 weeks to MVP with manual note upload. 3-5 months to first paying pilot customer (likely a forward-thinking medical group or small health system). 6-9 months to first meaningful recurring revenue ($5-10K MRR). 12-18 months to enterprise contracts if clinical validation data is compelling.

What people are saying
  • There's still the question of the quality and standardisation of the notes
  • tangential benefits like proper coding (hccs)
  • AI scribes are a spectrum and some work better than others
  • If they can show improvement there then there's at least a reason